Business
Patent notice of allowance granted for the US
Futura Medical PLC has received notice of allowance for a US continuation patent for MED3000 (Eroxon), extending protection for Eroxon and the women's product WSD4000 until 2040. This patent allowance is expected to trigger a US$2.5 million milestone payment from Haleon, bolstering the company's cash runway. The new patent's formulation claims enhance Futura's competitive position in the significant US erectile dysfunction market and protect its development product WSD4000. This adds to existing patent protection in Europe, Hong Kong, Taiwan, and China, further solidifying Futura's global intellectual property portfolio. Disclaimer*
About this update from Futura Medical Plc
[{"type":"text","content":"\n\n5 February 2026\nFutura Medical plc\n(\"Futura\", \"the Group\" or the \"Company\")\nPatent notice of allowance granted for MED3000 (Eroxon) in the US\n \nFutura Medical (AIM: FUM), the consumer healthcare Group behind Eroxon® and that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, announces that it has been granted notice of allowance of its US continuation patent (application number 19/252084) which will provide additional protection for Eroxon® (including formulation derivatives such as the Eroxon® Intense formulation) and women's product WSD4000 (currently in development) until 2040 in the US.\n \nThe new patent contains formulation claims that means the Company is confident that the granting of the patent (which is now expected before the end of Q2 2026) will trigger a US patent milestone payment of US$2.5 million under the terms of the Company's existing license agreement with Haleon.\n \nThis allowance adds to the Company's existing patent protection in Europe, Hong Kong, Taiwan and China, further consolidating its global IP. Other applications in additional markets remain pending.\nAlex Duggan, CEO of Futura, commented: \"The grant of this patent in the US will be a major milestone for Futura and is one of our key objectives for 2026. The receipt of the milestone payment will secure our cash runway to support current development opportunities. The United States is the largest global market for erectile dysfunction so importantly, this patent grant will provide an enhanced competitive position for both current and potential new formulations of Eroxon; in addition it will provide protection in the US for our development product WSD4000.\"\n \nThe information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014 as amended by the Market Abuse (Amendment) (EU Exit) Regulations 2019.\nContacts:\n\n\n\n\nFutura Medical plc\n \n \n\n\nAlex Duggan\nChief Executive Officer\nAngela Hildreth\nFinance Director and COO\n \n\n\[email protected]\n+44 (0)1483 685 670\nwww.futuramedical.com\n \n\n\n\n\nPanmure Liberum\nNominated Adviser\nand Broker\n\n\nEmma Earl, Will Goode, Mark Rogers (Corporate Finance)\n&nb...